DevCo Pharmaceuticals, Ltd.

Safety study of Lexipafant completed, phase III commences

Published in Elder Law Weekly, April 14th, 2004

DevCo Pharmaceuticals, Ltd., announced the successful completion of a confirmatory safety clinical trial of lexipafant.

Lexipafant is under late stage development for protection from organ dysfunction associated with coronary artery bypass graft (CABG), the treatment of HIV associated cognitive/motor dysfunction, and as a treatment for patients with acute pancreatitis. DevCo also announced that protocols and clinical trial material have been prepared and are available for an immediate start of phase III programs.

The double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and pharmacodynamic study formed part of DevCo's program...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Elder Law Weekly

Source: Elder Law Weekly (2004-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry